Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Anika Therapeutics (ANIK) Gross Profit: 2009-2024

Historic Gross Profit for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to $76.0 million.

  • Anika Therapeutics' Gross Profit fell 19.70% to $15.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.8 million, marking a year-over-year decrease of 4.47%. This contributed to the annual value of $76.0 million for FY2024, which is 7.92% down from last year.
  • Per Anika Therapeutics' latest filing, its Gross Profit stood at $76.0 million for FY2024, which was down 7.92% from $82.5 million recorded in FY2023.
  • Anika Therapeutics' 5-year Gross Profit high stood at $82.9 million for FY2021, and its period low was $69.0 million during FY2020.
  • For the 3-year period, Anika Therapeutics' Gross Profit averaged around $77.2 million, with its median value being $76.0 million (2024).
  • As far as peak fluctuations go, Anika Therapeutics' Gross Profit decreased by 19.61% in 2020, and later climbed by 20.16% in 2021.
  • Yearly analysis of 5 years shows Anika Therapeutics' Gross Profit stood at $69.0 million in 2020, then grew by 20.16% to $82.9 million in 2021, then decreased by 11.72% to $73.2 million in 2022, then climbed by 12.72% to $82.5 million in 2023, then dropped by 7.92% to $76.0 million in 2024.